Study to Assess Safety and Tolerability of Multiple Doses of EO2002

Inclusion criteria

All ocular criteria apply to the study eye unless otherwise noted.

• Age ≥ 18 years.
• Subject is phakic or pseudophakic with a posterior chamber intraocular lens (lens in the bag or sulcus).
• Symptomatic corneal edema associated with endothelial dysfunction which may be secondary to Fuchs' corneal dystrophy or pseudophakic bullous keratopathy.

Key Exclusion Criteria:

All ocular criteria apply to the study eye unless otherwise noted.

• Other corneal disease
• Anterior chamber intraocular lens
• Sutured or scleral-fixated intraocular lens.
• Macular disease that in the investigator and/or sponsor's opinion would limit the ability of the subject to demonstrate improvement in BCVA.
• History of refractive surgery.
• History of Vitrectomy
• Descemet membrane detachment.
• History of uveitis or other ocular inflammatory disease.
• History of incisional glaucoma surgery (e.g.,trabeculectomy, glaucoma drainage implant).
• IOP >21 or <7 mm Hg
• Prior incisional eye surgery within 3 months prior to study treatment or penetrating or endothelial keratoplasty.

• History of ocular neoplasm. 12. ETDRS BCVA in the fellow eye is worse than 35 letters (Snellen equivalent of 20/200).

• Female who is pregnant, nursing, or planning to become pregnant, or who is of childbearing potential and not using a reliable means of contraception during the study.

• Subject is currently participating in or has participated within the last 3 months in any other clinical trial of an investigational drug by ocular or systemic administration.

• Any concomitant medical or psychological condition that could interfere with study participation or is otherwise not suitable for entry into the study in the opinion of the investigator.